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ABSTRACT 
The role of proteases in viral infection of the lung is poorly understood. Thus, we 
examined MMP and cathepsin proteases in respiratory syncytial virus (RSV) infected 
mouse lungs. RSV induced gene expression for matrix metalloproteinases (MMP) -2, -3, 
-7, -8, -9, -10, -12, -13, -14, -16, -17, -19, -20, -25, -27, -28 and cathepsins B, C, E, G, H, 
K, L1, S, W and Z in the airways of FVB/NJ mice. Increased proteases were present in 
the bronchoalveolar lavage fluid (BALF) and lung tissue during infection. Mitochondrial 
antiviral-signaling protein (Mavs) and Trif deficient mice were exposed to RSV. Mavs 
deficient mice had significantly lower expression of airway MMP-2, -3, -7, -8, -9, -10, -
12, -13 and -28 and cathepsins C, G, K, S, W and Z. In lung epithelial cells, retinoic 
acid–inducible gene-1 (RIG-I) was identified as the major RIG-I- like receptor (RLR) 
required for RSV induced protease expression via MAVS. Overexpression of RIG-I or 
treatment with IFN-β in these cells induced MMP and cathepsin gene and protein 
expression. The significance of RIG-1 protease induction was demonstrated by the fact 
that inhibiting proteases with batimastat, E64 or ribavirin prevented airway 
hyperresponsiveness and enhanced viral clearance in RSV infected mice. 
 
 
 
 
 
 
 
 4 
INTRODUCTION 
Microbial infections in the airways contribute to tissue remodeling and are also a major 
factor in exacerbating underlying diseases, which have been associated with cytokine and 
chemokine release from resident lung cells1. A protease/antiprotease imbalance can 
equally be associated with inflammation and extracellular matrix degradation2. Proteases 
have a number of functional effects that contribute to tissue destruction including tissue 
remodeling, cleavage of soluble innate factors and activation of receptors. Alternatively, 
proteases also play a critical role in microbial clearance as neutrophil proteases are 
critical for microbial killing3. However, some proteases may even facilitate viral entry 
and replication into human cells4. Thus, determining how viral infection impacts on 
protease expression, release and activity and the subsequent protease effects on immune 
responses and lung microenvironment remain important areas to explore. 
Matrix metalloproteinases (MMPs) and cathepsins are clinically important 
proteases that are elevated in many diseases. MMPs are produced by a wide variety of 
cell-types, including epithelium, fibroblasts, neutrophils, and macrophages5. MMPs act 
on a variety of non-matrix extracellular proteins, such as cytokines, chemokines, 
receptors, junctional proteins, and antimicrobial peptides, to mediate a broad range of 
biological processes, such as repair, immunity, and angiogenesis5. Similarly, cathepsins 
are produced by several cell types and tissues and are known to undergo activation by 
cytokines6. Respiratory syncytial virus (RSV) is a virus frequently reported in infants, the 
elderly, immunocompromised patients as well as healthy adults7. Infection alters protease 
profiles, with MMP-3 and -10 expression being sensitive to RSV inoculation in nasal 
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epithelial cells8 and MMP-3 levels in nasopharyngeal aspirates are associated with RSV 
disease severity9. RSV induces MMP-9 gene expression in human bronchial epithelial 
cells10 and MMP-9 and -2 were activated by RSV in BALB/c mouse11. Bovine RSV can 
act synergistically with Histophilus somni supernatant to elevate MMP-1 and -3 levels, 
leading to enhanced collagen breakdown and facilitating viral infection efficiency in 
bovine alveolar type-2 cells12. Therefore, previous studies show that RSV induces several 
proteases and suggest that RSV-inducible proteases may play a major role in disease 
progression. Proteases become expressed in response to microbial product stimuli13 with 
pathogen recognition receptors playing a major role in protease gene regulation when 
utilizing microbial mimicking agonists14, 15. Pathogen recognition receptors (PRR), such 
as TLRs and retinoic acid–inducible gene-1 (RIG-I)-like receptors (RLRs), induce major 
signaling cascades in response to viral stimulation16. Both TLR mediated Trif signaling 
and RLR can modulate similar immune processes to regulate cytokine production17, 18. 
The viral load of RSV correlates with the mRNA levels of the RLR, RIG-I19. RIG-I and 
melanoma differentiation-associated protein 5 (MDA5) activate the mitochondrial 
antiviral-signaling protein (MAVS) to trigger an antiviral response20. However, little is 
known about the role of PRRs in RSV-induced protease expression; although proteases 
have been shown to modulate TLR3 and RIG-I signaling21 and inhibition of MMP-9 
activity in bronchial epithelial cells prevents syncytia formation and blocks RSV 
multiplication10. Therefore, profiling the protease response during RSV infection and 
characterizing their regulation and role in disease progression may be beneficial for 
future treatment of RSV infection. 
 6 
In this study, we investigate MMP and cathepsin expression responses to RSV 
infection. In vivo and in vitro approaches were utilized to identify the major regulatory 
signaling pathways in RSV-induced protease expression. The influence of Trif and 
MAVS signaling pathways were examined on RSV-induced protease expression, with 
RLR dependent MAVS signaling observed to play a major role in RSV-induced MMP 
and cathepsin expression. These findings indicate that viral infections significantly 
enhance host protease responses, in a type-I interferon dependent mechanism. 
Furthermore, we show that the RLR pathways are key players in the host protease 
response to viral infection and inhibition of proteases may be beneficial in clearing RSV 
from the airways. 
 
RESULTS 
RSV infection induces MMP and cathepsin expression and activity 
Increased protease levels have been frequently observed in human airway diseases22 and 
play a critical role in microbial killing3. While it is established that a viral induced host 
proteases response occurs, when and which proteases are induced in RSV infected lungs 
is not yet elucidated. Here we show that mice exposed to RSV infection have increased 
airway collagenase and elastase activity in their BALF (Figure 1A). Elastase activity was 
observed as early as 24 hours post infection. Both elastase and collagenase activity 
persisted beyond 9 days post RSV challenge. Protease activity mimicked the RSV N copy 
number and viral titer within the lung tissue, with reduced protease activity observed 
upon RSV clearance (Figure 1B). RSV infected mice also lost weight during infection 
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(Figure 1C) and had increased BALF immune cell infiltration (Figure 1D). Not 
surprisingly, RSV infection resulted in an infiltration of macrophages, neutrophils and 
lymphocytes into the lung (Figure 1D-E).  
The influence of viral infection on protease expression was investigated in greater 
detail via qPCR by examining the MMP and cathepsin families of proteases. Mice 
infected with RSV have significant gene expression increases for MMP-2, -3, -7, -8, -9, -
10, -12, -13, -14, -16, -17, -19, -20, -25, -27 and -28 (Figure 2A-H). Additionally, 
cathepsins B, C, E, G, H, K, L1, S, W and Z were all enhanced by RSV infection (Figure 
2I-M). Of note, 9 days post RSV lung infection MMPs -2, -8, -9, -10, -12, -13, -14, -16, -
19, -25, -27, -28 and cathepsins E, G, K, L1, S, W and Z remained significantly increased 
in RSV infected lungs (Figure 2). Protein analysis was performed to confirm qPCR data. 
As illustrated in Figure 3, RSV infection enhanced BALF and lung tissue MMP and 
cathepsin protein levels and activity. MMP-2, -3, -8, -9 and -12 BALF protein levels were 
quantified by multiplex analysis (Figure 3A). RSV infection increased BALF gelatinase 
activity, which demonstrated an early MMP-9 response and a later MMP-2 response to 
RSV challenge (Figure 3B). Western blot on lung tissue confirmed that RSV exposure 
increased cathepsin E, S, G, K, B, W and Z levels 7 days post infection (Figure 3C). 
Cathepsin B, G and S activity levels were elevated in BALF from RSV infected mice 
(Figure 3D).  
RSV induces the MAVS/MDA5/RIG-I/TLR3 pathways in mouse lungs 
RSV increased protein levels of MDA5, RIG-I, MAVS, MyD88 and Trif (Figure 4A). 
Additionally, phosphorylation of IRF3 and TBK1 were observed following RSV 
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infection (Figure 4A). NF-κB and AP-1 activity were induced by RSV 24 hours post 
challenge and continued to persist beyond 9 days (Figure 4B). As the TLR3/4 and RLR 
pathways were altered by RSV19, Trif and Mavs KO mice were used to examine the 
importance of these pathways on protease production in vivo. Mavs KO mice were 
utilized as MAVS links RIG-I and MDA5 to antiviral effectors responses. Trif KO mice 
were chosen as both TLR3 and TLR4 are activated by RSV and are the only TLRs that 
utilize Trif signaling. Mice were exposed to RSV and euthanized every second day until 
9 days post RSV challenge. Gene expression studies were performed on days post RSV 
challenge that corresponded with the maximal level of gene expression for each protease 
as determined in Figure 2. Loss of Mavs expression prevented RSV-induced MMP-2, -3, 
-7, -8, -9, -10, -12, -13 and -28 and cathepsins C, G, K, S, W and Z gene expression 
(Figure 5). Loss of Trif expression altered the RSV induced gene expression of MMP-8, 
-28 and cathepsins G, K, L1, S and Z (Figure 5). Interestingly, Trif expression 
suppressed cathepsin G gene expression (Figure 5). Tissue and BALF protein analysis 
confirm Trif or Mavs regulation of protease expression (Figure 6A-B). Loss of Mavs 
impacts on tissue levels of cathepsin E, G, K, S, W and Z (Figure 6A) and BALF levels 
of MMP-2, -3, -8, -9 and -12 (Figure 6B). Loss of Trif impacted on cathepsin S tissue 
levels (Figure 6A). Additionally, Trif and Mavs KO mice displayed a similar loss in body 
weight following RSV infection as wild-type mice (Figure 6C) but loss of Mavs or Trif 
resulted in a greater viral load in the airway tissue on day 9 following infection compared 
to wild-type mice (Figure 6D). 
Type-I interferon responses regulate RSV induced protease expression in human 
SAE cells  
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RSV is known to readily infect the airway epithelium23 and is detectible in the airways 
using immunofluorescence (Figure 7A). Therefore to confirm our in vivo findings and 
identify which RLR is regulating MAVS induced protease production; human airway 
epithelial cells were infected with RSV and protease expression profiles analyzed by 
qPCR (Figure 7). Gene expression for MMP-1, -3, -7, -8, -9, -10, 12 and 13 were 
induced in SAE cells upon RSV infection (Figure 7B) but were not observed when RSV 
was UV-treated (Supplemental Figure S1A). Multiplex analysis demonstrated that 
increased MMP-1, -3, -7, -8, -9, -10 and -13 were observed in the media of RSV infected 
cells (Figure 7C). Only cathepsins E and G were induced in SAE cells upon RSV 
infection (Figure 7D and Supplemental Figure S1B). Interestingly, using an 
immunofluorescence approach, only cells positive for RSV antigen had increased MMP-
9 and cathepsin E (Figure 7E). The tissue inhibitors of metalloproteinases (TIMPs)-1, -2 
and -3 were unaltered by RSV stimuli in SAE cells, as observed in the media from SAE 
cells (Supplemental Figure S2).  
Since RSV induced a wide range of the proteases in a similar manner to that 
observed in vivo, SAE cells were transfected with siRNA for Trif, MDA5, RIG-I, LGP2 
and MAVS (see Supplemental Figure S3 for siRNA transfection efficiency) to confirm 
the in vivo data but also to determine the RLR responsible for this protease induction. 
Several of the siRNAs altered protease expression, however RIG-I and MAVS expression 
were critical for the majority of RSV-induced proteases (Table 1). This is of interest as 
RSV viral load correlates with RIG-I mRNA levels in a study of bronchiolitis in infants19. 
In fact, overexpression of RIG-I in SAE cells up-regulated the same proteases as RSV 
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stimulation (Figure 8). Therefore, these results show that RLRs, such as RIG-I, plays a 
major role in RSV-mediated protease expression. 
As RIG-I signaling regulates RSV-induced protease expression, type-I interferon 
stimulus was examined for induction of protease expression. SAE cells treated with 1000 
units of recombinant human IFN-β lead to gene expression induction of the same 
proteases seen in RSV stimulation (Figure 8C-D). Equally, silencing the interferon-α/β 
receptors (IFNAR1 and 2) moderately subdued RSV from inducing gene expression of 
MMPs and cathepsins (Figure 8E). Therefore RSV induced protease expressions are in 
part an indirect effect of elaborated cytokines, such as a type-I interferon response. 
Inhibition of protease activity enhanced RSV clearance from the airways 
Protease inhibitors were utilized in vivo to assess the functional role of enhanced 
proteases in the airways during RSV infection. Wild-type animals were administered a 
MMP inhibitor (batimastat) or cathepsin inhibitor (E64) daily during RSV infection. 
Batimastat, a potent inhibitor of MMP -1, -2, -3, -7 and -9, and E64, an effective cysteine 
protease inhibitor, were intraperitoneal (IP) administered daily. An anti-viral drug, 
ribavirin, was also administered to a group of animals as ribavirin is administered to 
patients with severe RSV infection. Also, ribavirin can inhibit MMP-9 activity in THP-1 
cells24. Animals were euthanized 7 days post RSV challenge and all measurements are on 
this day. In vivo administration of batimastat and E64 significantly inhibited protease 
activity in the airways (Figure 9A-B). Interestingly, ribavirin treatment prevented 
protease activity in mouse airways during RSV infection (Figure 9A-B). This inhibition 
was comparable to both the protease inhibitors. Animals receiving a protease inhibitor or 
ribavirin did not lose weight during the week of infection and demonstrated faster 
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clearance of RSV from the airways (Figure 9C-D). Surprisingly, there were reduced 
immune cells recruited to the airways in animals receiving protease inhibitor or ribavirin 
(Figure 9D). Inhibition of proteases also subdued RSV induced airway 
hyperresponsiveness, demonstrated by respiratory system resistance (Rrs) measurements 
during a methacholine dose challenge (Figure 9E). IL-4 plays a major role in allergic 
response to RSV infection resulting in the development of airway hyperresponsiveness 
and lung eosinophilia25. Animals receiving a protease inhibitor or ribavirin had reduced 
IL-4 responses to RSV (Figure 9F), which may contribute to the changes in airway 
hyperresponsiveness to RSV. IFN-β levels were unaltered in all animal groups infected 
with RSV (Figure 9F). 
 
DISCUSSION 
Several studies have investigated the induction of proteases by RSV as early as 199926 
but the role of these protease families in disease severity and viral clearance has not been 
established. We characterized how two families of proteases respond to RSV infection 
and demonstrate that the induction of proteases by RSV is primarily regulated by RLRs, 
such as RIG-I, in a type-I dependent manner. Prior to this study, RSV infections were 
known to induce proteases, such as neutrophil elastase26 and MMP-911, but little was 
known about the influence of RSV infection on protease expression and the subsequent 
impact on the lung. We demonstrated that RSV induces expression of protease networks 
that contribute to disease progression. This study highlights the impact of RSV infection 
on the proteolytic response within the airways and the potential to target proteases to treat 
RSV infection. 
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Prior to undertaking this study, we believed that RSV induced proteases were 
enhanced via a TLR3/Trif dependent manner, as polyinosinic-polycytidylic acid 
(poly(i:c)), a synthetic analog of double-stranded RNA (dsRNA),  enhanced several 
MMPs14, 15 and TLR3/Trif are significantly induced by RSV. However, TLR3/Trif only 
partially regulated the protease response and RIG-I exerted a far more substantial effect 
on airway proteases responses. RLRs largely recognizes dsRNA, which is produced 
during the replication of many viruses27. Sendai virus defective interfering (DI) RNA28 
and the genomic “panhandle” structure of influenza virus29 activate RLR signaling. It has 
been speculated that these “panhandle” structures allow negative-strand RNA viral 
genomes to achieve partially double-stranded RNA30. Exactly how RNA triggers the 
RLR pathway for most RNA viruses, including RSV, has yet to be identified. In 
rhinovirus studies, the bronchial epithelium anti-viral response initially requires 
recognition of rhinovirus infection by TLR3/TRIF and a subsequent RNA helicases 
response16, suggesting a contribution of both pathways. Indeed, RSV-induced TLR3 is 
regulated by RIG-I-dependent IFN-β that is mediated by both IFN response-stimulated 
element (ISRE) and signal transducer and activator of transcription (STAT) sites in its 
proximal promoter32. In this manner, TLR3 does not affect RSV-induced NF-κB 
binding32, which may alter the regulation of certain proteases. RIG-I regulated IFN-β 
secretions from infected cells could lead to the Trif activation observed here and the 
IFNAR1 and 2 receptor induction, which represent two plausible and distinct 
mechanisms to induce protease production. Therefore, MAVS not only links RIG-I and 
MDA5 to antiviral effector responses, MAVS can also regulate the RIG-I inducible 
proteases response to RSV observed in this study. 
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Recently, investigators have identified several proteases associated with RSV 
infection, such as MMP-2, -3, -9 and -108-11. We have identified that RSV enhances 
MMP-2, -3, -7, -8, -9, -10, -12, -13, -14, -16, -17, -19, -20, -25, -27, -28 and cathepsins B, 
C, E, G, H, K, L1, S, W and Z levels in mouse airways. Whether all of these proteases are 
present in human viral exacerbations or contribute to disease progression is not yet 
known but each protease represents many potential future topics of interest. Also it 
should be noted that RSV gave a robust MMP-1 induction in SAE cells, which could not 
be evaluated in vivo, as mice express no MMP-1. Indeed the protease profile in mice and 
epithelial cells differed with expression for MMP-2, -14, -17, -20, -25, -27, -28 and 
cathepsins B, C, H, L1, S, W and Z but its is not surprising as other residential cells or 
infiltrated immune cells could also contribute to protease production in response to RSV. 
The functional role of proteases in airway remodeling is well documented5 but the impact 
of so many proteases on the microenvironment of the lung is unclear. Our data 
demonstrates that inhibition of protease activity aids in viral clearance and others have 
demonstrated that inhibition of MMP-9 activity prevents syncytia formation and blocks 
RSV multiplication10, which suggests resolving the select protease activity in RSV 
infection is beneficial. These data strengthen the case for the use of protease inhibitors to 
treat RSV infections. Identifying the exact protease(s) responsible for aiding viral 
infectivity represents a major future area of investigation. Ribavirin administration to 
mice prevented the activity of proteases but also gene expression of several proteases, 
including MMP-9, -10, -12 and cathepsins B, C and S (Figure S4). Expression of MMP-
9 represents the most likely candidate for the changes in the phenotype observed in our 
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study as MMP-9 KO mice have reduced airway hyperresponsiveness33 and inhibition of 
MMP-9 blocks RSV10 and fellow Paramyxoviruses, Sendai virus34. 
Other viruses have been documented to induce protease responses. Indeed, the 
induction of MMP-9 by Influenza A virus was associated with severe lung pathology in 
mice35 and the regulation of neutrophil migration36. Also, MMP-9 is higher in children 
with mumps meningitis37. Sendai virus increases MMP-9 activity to drive pneumonia 
progression by enhancing virus multiplication and aids in the destruction of lung matrix 
in rats34. Whether other viruses lead to the induction of similar host proteases as RSV or 
play a similar role in disease progression is a major topic for discussion. Our in vitro 
RIG-I overexpression experiment suggests that multiple viruses, which trigger a RIG-I 
response, may observe a similar protease response. Also, poly(i:c) triggers the expression 
of multiple MMPs15, which further suggests the potential for similar mechanistic protease 
induction. Other PRRs ligands can induce expression of proteases, such as LPS induction 
of MMP-114, 15 or multiple TLR ligands induction of MMP-9 expression14. Therefore, the 
protease profile induced by other microorganisms and the role of subsequent induced 
proteases in disease progression remains an intriguing area for future study. RSV could 
also induce many other proteases outside of the MMP and cathepsin families. Neutrophil 
elastase has been documented to be elevated in the upper airways of infants infected with 
RSV26. Similarly, we observed increased elastase activity following RSV infection, 
which may not only be due to increased MMP-12. Interestingly RSV does induce 
ADAM17 in mouse airways (Supplemental Figure S5A). RSV induction of membrane 
localized ADAM protease activity has been linked to the activation of ERK and IL-8 
production in a EGFR dependent manner38. In our in vitro models RSV also induced 
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emmprin, an inducer of MMP synthesis (Supplemental Figure S5B). Emmprin 
expression affects the production of MMPs39 and its expression has been linked to 
pulmonary fibrosis progression40 and may contribute to the signaling outlined in this 
study. Therefore it is conceivable that other families of proteases may also become 
induced in viral infections and lead to the induction of multiple signaling pathways, 
which would represent an area that merits further investigation. 
 Neutrophil derived proteases play an important role in micro-flora clearance, with 
mice deficient in neutrophil-granule proteases unable to resist staphylococcal and 
candidal infections3. However little is know about the antimicrobial functions of protease 
networks, especially with viral infection. Prior to this study it was unclear whether the 
host protease response was required to clear the microbial infection or whether the 
protease release would have an overall negative impact on lung inflammation and 
remodeling. Due to the numerous proteases induced by RSV, it is out of the scope of this 
manuscript to investigate the functional role of each protease in response to RSV but 
through the use of broad-spectrum protease inhibitors we have determined the impact of 
proteases on RSV infection and airway hyperresponsiveness to metacholine challenge. 
Further work is required to determine whether the inhibition of IL-4 by protease 
inhibitors is the primary impact on preventing RSV induced airway hyperresponsiveness 
by protease inhibitors or ribavirin. As IL-4 plays a major role in allergic response to RSV 
infection through the development of airway hyperresponsiveness and lung 
eosinophilia25, it is conceivable that protease regulation of IL-4 may play a major role in 
disease symptoms. The beneficial effects of inhibiting cathepsins was surprising as 
cathepsin activity regulates TLR9 interaction with CpG, thereby regulating TLR9 
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immunity41. However recent evidence suggests that cathepsin S can lead to the formation 
of soluble TLR9 that inhibits TLR9 signaling42. Cathepsin S activity was inhibited by 
E64 and ribavirin. In fact, ribavirin inhibited cathepsin S gene expression. Recent studies 
suggest that several of the proteases highlighted in this study could contribute to 
macrophage migration, invasion, differentiation and maturation, such as MMP-1043, 
MMP-1944 and MMP-2845. However, further studies are required to investigate their 
functional roles here. 
In summary, our studies demonstrate that RSV acts in a RLR dependent manner, 
most likely via RIG-I signaling via type-I IFN, to augment airway protease responses in 
the lung. Inhibition of protease activity prevented RSV induced airway 
hyperresponsiveness and lead to enhance clearance of the virus. These findings provide 
important new insights into the elaborate network of proteases triggered by RSV lung 
infection.  
 
METHODS 
RSV culture. Human RSV strain A2 (ATCC, Manassas, VA; #VR-1540) was cultured 
and virus titers quantified in Hep2 cells by performing plaque assays, as previously 
described1. Briefly, the virus was allowed to grow for 5 days at 37°C in a 5% CO2 
atmosphere. The infected Hep2 monolayers were collected and the virus was released by 
sonication. Cell debris was removed by centrifugation at 2,500 x g for 5 minutes at 4°C. 
Virus was collected by centrifuging the supernatant for 2 hours at 22,000 x g at 4°C. 
Virus were suspended in culture media and snap frozen and maintained at -80oC. Non-
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infected Hep2 cell cultures were processed in the same manner as RSV infected cells and 
the resulting sample collection was used as a mock control.  
Animal models. Trif (Ticam1) and Mavs knockout (KO) mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME) and breed on to a FVB/NJ background at least 6 
generations. All mice were maintained in a specific pathogen-free facility at Mount Sinai 
Roosevelt’s Hospital. 8-week-old mice were used at the initiation point for all 
experiments and each experimental parameter had 12 animals per group. Mice were 
anesthetized by intraperitoneal injection of a mixture of ketamine and xylazine. Animals 
were intranasally administered 1x106 plaque forming units (pfu) of RSV or mock. Mock 
and RSV infection animals were euthanized every second day up to 9 days post 
challenge. Animals were weighed daily. BALF and lung tissue were collected for 
analysis of protease levels. Immune cell counts were determined by microscopy and cell 
type determined by quick diff staining. All animal experiments were performed with 
approval from Mount Sinai Roosevelt’s Hospital Center’s Institutional Animal Care and 
Use Committee approval at Mount Sinai School of Medicine.  
Lung titers and RSV N copy number. Lungs of infected mice were excised and 
homogenized using a mechanical homogenizer (Kinematica, Bohemia, NY, USA). The 
viral titers in the homogenates were quantified by plaque assay on Hep2 cells, as 
previously described1. The concentration of RSV N (pg) was determined by PCR based 
on a standard curve. The following primers were used at 100 pmol each: 5′-TGG GAG 
AGG TAG CTC CAG AA-3’ and 5’-AGA ATC TGT CCC CTG CTG CTA-3’. Ct was 
plotted against known RSV standards. Results are represented as natural log pico grams 
(pg). 
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Cell culture. Monolayers of human SAE cells from healthy subjects (Lonza, 
Walkersville, MD) were submerged cultured. All cells are assayed and test negative for 
HIV-1, mycoplasma, Hepatitis-B, Hepatitis-C, bacteria, yeast and fungi upon isolation by 
Lonza. Cells were only used for experiments at passages 3-6 and at a confluency of 
approximately 70%. SAE cells were transfected by administering silencing RNA 
(siRNA) for MDA-5, RIG-I, Trif, MAVS, LGP2, IFNAR1, IFNAR2 or control siRNA 
(Qiagen, Gaithersburg, MD). Cells were treated with RSV at a MOI of 0.3 for 24 hours. 
Cells were also treated with mock control as described above. Additionally, SAE cells 
were transfected with either an empty vector (Origene, Rockville, MD; pCMV6-Entry) or 
with the same vector that overexpresses RIG-I (DDX58) as recommended by the 
manufacturers (Origene). Human recombinant IFN-β protein (EMD Millipore) was 
administered to SAE cells at 1000 Units (U) cells for 24 hours. 
MMP and cathepsin measurements. MMP and cathepsin gene expression was 
performed by quantitative PCR (qPCR) using validated Taqman probes (Life 
Technologies/Applied Biosystems, Carlsbad, CA). All qPCR results are represented as 
relative quantification (RQ) compared to the mock treated animals and corrected to actin 
levels. Several MMP levels were measured in BALF and cell culture supernatants using a 
bead assay (MILLIPLEX MAP MMP Magnetic Bead Panels, EMD Millipore, Billerica, 
MA) with the BioRad Bio-Plex 200 system (BioRad, Hercules, CA). Cathepsin tissue 
levels were determined by immunoblots and BALF cathepsin S and B activity assays as 
previously described46. Cathepsin G BALF activity was determined by a commercial 
available colorimetric assay (Abcam; ab126780). BALF collagenase activity was 
determined by a colorimetric ninhydrin method, as previously described22. Proteinase 
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activity was also assessed with the same colorimetric ninhydrin method but utilizing 
casein as the substrate. BALF elastase activity was measured by the hydrolysis of N-
succinyl-L-Ala-L-Ala-L-Ala-p-nitroanilide(Suc Ala3NA) per minute at 25°C and pH 8.0. 
BALF gelatinase activity was determined by gelatin zymography. 
Intracellular signaling. Lung tissue protein from mice was homogenized in radio-
immunoprecipitation assay (RIPA) buffer, centrifuged at 13,000 x g for 10 minutes and 
supernatants collected. Immunoblots were conducted to determine levels of cathepsin E, 
S, G, K, B, W, Z (all cathepsin antibodies from Santa Cruz Biotechnology, Paso Robles, 
CA), MDA5, RIG-I, MAVS, Trif, MyD88, p-IRF3(Ser396), IRF3, p-TBK1(Ser172), 
TBK1/NAK and actin (all remaining antibodies from Cell Signaling Technologies, 
Danvers, MA). Chemiluminescence detection was performed using the Bio-Rad 
Laboratories Molecular Imager ChemiDoc XRS+ imaging system. Densitometry was 
performed on each target and represented as a ratio of pixel intensity compared to actin, 
using Bio-Rad Laboratories Image Lab software (version 4.0, build 16). NF-ĸBp65 and 
AP-1 levels were measured on the nuclear protein extracts using specific activation 
assays from Active Motif (46096 and 40096; Active Motif, Carlsbad, CA, USA). 
Relative transcription factor activity is represented as a percentage compared to the mock 
treated group. 
Immunofluorescence. Immunoreactivity assays were performed on SAE cells with 
polyclonal anti-RSV (Abcam; ab20745), anti-MMP9 (Cell signaling Technologies; # 
2270) and anti-cathepsin E (Santa Cruz biotechnologies; sc-166343) antibodies. Mouse 
lung tissue was also examined for RSV immunoreactivity.  
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Airway responses to methacholine challenge. Airway responses to methacholine 
(Sigma Chemical, St. Louis, MO) were assessed with the Scireq Flexivent system 
(Scireq, Montreal, QC, Canada) at 1-week post RSV challenge and daily intraperitoneally 
(IP) injections of vehicle (20% DMSO), 60 mg/Kg batimastat, 5 mg/Kg E64 or 30 mg/Kg 
ribavirin. Animals were anesthetized with ketamine/xylazine (10 mg/kg) and paralysis 
was induced with 1 mg/kg pancuronium bromide IP (Sigma). The linear single-
compartment model was used to assess total respiratory system resistance (Rrs). 
Methacholine dose responses were determined. 
Statistical analyses. For statistical analysis, data from 12 animals or multiple separate 
cell experiments were pooled. Data are expressed as means ± S.E.M. Differences 
between groups of mice over time were compared by two-way analysis of variance 
(ANOVA). Individual differences between groups were tested by multiple comparison 
and analysis using the Bonferroni post-test. Pairs of groups were compared by Student’s t 
test (two tailed). p values for significance were set at 0.05. All analysis was performed 
using GraphPad Prism Software (Version 5 for Mac OS X).  
 
SUPPLEMENTARYMATERIAL is linked to the online version of the paper at 
http://www.nature.com/mi 
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FIGURE LEGENDS 
Figure 1 RSV infection induces protease activity in the airways. FVB/NJ mice were 
infected with 1x106 pfu of RSV and a group of animals were euthanized at day 0, 1, 3, 5, 
7 and 9 post infection. (A) BALF had greater collagenase and elastase activity in animals 
infected with RSV compared to mock controls. (B) RSV N copy number and viral load 
were greatest 5 days post RSV challenge and were at the lower level of detection by day 
9.  (C) RSV infection resulted in a significant drop in body weight in animals and (D) an 
increase in BALF cellularity. Graphs are represented as mean ± S.E.M., where each 
measurement was performed 3 times on 12 animals/group. * and ** represents a p value 
less than 0.05 compared to mock treated mice or day 1 RSV treated mice, respectively. p 
values shown comparing RSV to mock treated mice connected by a line. (E) 
Representative images of mice lungs from each RSV treated group (scale bar=10 µM). 
Figure 2 RSV infection induces MMP and cathepsin gene expression. FVB/NJ mice 
were infected with 1x106 pfu of RSV and animals were euthanized every second day as 
previously described. (A-H) MMP and (I-M) cathepsin lung gene expression were 
analyzed by qPCR. Graphs are represented as relative quantification (RQ) of the mean ± 
S.E.M, with each measurement performed 3 times on 12 animals/group. *Represents a p 
value less than 0.05 compared to mock treated mice on each corresponding day.  
Figure 3 RSV infections induce MMP and cathepsin protein expression and activity. (A) 
BALF MMP-2, -3, -8, -9 and -12 levels were determined by multiplex analysis on mock 
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treated and RSV treated animals. (B) Gelatinase activity was analyzed in BALF using 
gelatin zymography. Bands corresponding to MMP-2 and MMP-9 are highlighted. (C) 
Cathepsin E, S, G, K, B, W and Z lung protein levels were analyzed by immunoblotting 
and corresponding densitometry analysis. (D) Cathepsin B, S and G activity levels were 
determined in BALF. FI represents fluorescent intensity. Graphs are represented as mean 
± S.E.M, where each measurement was performed 3 times on 12 animals/group. 
*Represents a p value less than 0.05 compared to mock treated mice. p values shown, 
comparing both treatments connected by a line. 
Figure 4 RSV induces the MAVS/MDA5/RIG-I/TLR3 pathways in mouse lungs. (A) 
Immunblots were performed to examine levels of MDA, RIG-I, MAVS, MyD88 and 
TRIF protein and IRF3 and TBK1 phosphorylation in lung tissue of RSV infected 
animals. Densitometry analysis was performed against actin or total protein (TBK1 and 
IRF3) levels for all samples from multiple immunoblots. (B) NFκB and AP-1 nuclear 
activity levels were determined in the lung tissue of mock and RSV treated mice. Graphs 
are represented as mean ± S.E.M, where each measurement performed 3 times on 12 
animals/group. *Represents a p value less than 0.05 compared to mock treated mice on 
each corresponding day. 
Figure 5 MAVS is required for the gene expression of the majority of RSV inducible 
airway proteases. Wildtype, Trif (Ticam1) and Mavs KO mice were infected with 1x106 
pfu of RSV and animals were euthanized every second day as previously described.  
MMP and cathepsin gene expression in lung tissue was analyzed by qPCR on the day 
post infection with the maximal level of gene expression for each protease, as determined 
in Figure 2. MMP-10 and -20 were examined one-day post infection. MMP-7, -8, -9 and 
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cathepsin B were examined three days post infection. MMP-3, -16 and -17 were 
examined five days post infection. MMP-2, -12, -13, -14, -19, -25, -27, -28, cathepsin C, 
L1, S, W and Z were examined seven days post infection. Cathepsin E, G, H and K were 
examined nine days post infection. Results are represented as relative quantification (RQ) 
of the mean ± S.E.M when compared to mock treated animals on each corresponding 
day, with each measurement performed 3 times on 12 animals/group. p values shown, 
comparing treatments connected by a line. 
Figure 6 MAVS is required for the protein expression of the majority of RSV inducible 
airway proteases. (A) Immunoblots (Cathepsin E, G, K, S, W, Z, MMP-14, MMP-28 and 
actin) were performed on lung tissue 7 days post RSV challenge and densitometry 
analysis was determined. The Y-axis represents densitometry value for all graphs. (B) 
Multiplex analysis (MMP-2, -3, -8, -9 and -12) was performed on BALF 7 days post RSV 
challenge. (C) RSV infection resulted in a drop in body weight in all animal groups and 
(D) a significant increase in the viral load 9 days post RSV challenge in the Mavs KO 
mouse group compared to mock treated mice. Graphs are represented as mean ± S.E.M., 
where each measurement was performed 3 times on 12 animals/group. p values shown, 
comparing both treatments connected by a line. *Represents a p value less than 0.05 
comparing Mavs KO mice to wildtype mice 9 days post RSV challenge. 
Figure 7 The MMP and cathepsin gene expression profile in human SAE cells exposed 
to RSV. (A) Immunofluorescence was performed on tissue from mock or RSV infected 
mice 5 days post RSV challenge with an antibody that recognizes RSV antigen (red). (B) 
MMP gene expression was performed in SAE cells treated for 24 hours with mock or 
RSV was analyzed by qPCR. (C) MMP-1, -3, -7, -8, -9, -10 and -13 in cell culture 
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supernatants were determined by multiplex analysis following RSV infection. (D) 
Cathepsin gene expression was performed in SAE cells treated for 24 hours with mock or 
RSV was analyzed by qPCR. (B and D) Dotted line represents mock treated level of 
expression. *Represents a p value less than 0.05 compared to mock treated mice. (E) Co-
immunofluorescence was performed on cells for either MMP-9 or cathepsin E (green) 
and with an antibody that recognizes RSV antigen (red) (Scale bars are 20 μm). Merged 
images demonstrate co-localization (orange). Graphs are represented as mean ± S.E.M, 
where n=10 per group. p values shown, comparing both treatments connected by a line. 
Figure 8 Overexpression of RIG-I in human SAE cells and IFN-β stimulation induces 
protease expression. (A) MMP and cathepsin gene expression was performed on SAE 
cells transfected with either an empty vector (pCMV6-Entry) or with the same vector 
overexpressing RIG-I (DDX58). Immunoblots were performed to determine RIG-I 
protein levels compared to actin and three individual transfections are presented. (B) 
MMP-1, -3, -7, -8, -9, -10 and -13 media levels were determined by multiplex analysis 24 
hours following RSV infection. (C) MMP and cathepsin gene expression were 
determined in SAE cells following treatment with 1000 units of recombinant human IFN-
β for 24 hours. (D) Supernatant levels of MMP-8, -9, -10 and -13 following IFN-β 
stimulation. (E) MMP and cathepsin gene expression was performed on SAE cells 
transfected with siRNA for IFNAR1, IFNAR2 or both and treated with RSV. 
Immunoblots were performed to determine protein silencing compared to actin and two 
individual transfections are presented. All graphs are represented as mean ± S.E.M, 
where n=10 per group. *Represents a p value less than 0.05 compared to empty vector-
transfected cells. 
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Figure 9 Administration of protease inhibitors or ribavirin aid in RSV clearance and 
subdue airway hyperresponsiveness in mice. FVB/NJ mice were injected with vehicle, 
bastimastat, E64 or ribavirin prior to infected with 1x106 pfu of RSV and animals 
received daily following-up injections until they were euthanized at day 7-post infection. 
BALF (A) collagenase, casein degradation capability, cathepsin S and G elastase activity 
and (B) gelatinase activity were determined in all animals groups. (C) Animal body 
weight, (D) BALF cellularity and RSV N copy number were determined in all animals.  
(E) Airway hyperresponsiveness to increasing doses of methacholine was assessed in 
each animal group. (F) IL-4 and IFN-β gene expression in lung tissue was analyzed by 
qPCR. Graphs are represented as mean ± S.E.M., where each measurement was 
performed 3 times on 12 animals/group. * and ** represents a p value less than 0.05 
compared to mock and vehicle treated mice or RSV and vehicle treated mice, 
respectively.  
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